- Home
- BODI vs BOLD Comparison
BODI vs BOLD Comparison
Compare BODI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- BOLD
- Stock Information
- Founded
- BODI 1998
- BOLD 2018
- Country
- BODI United States
- BOLD United States
- Employees
- BODI N/A
- BOLD N/A
- Industry
- BODI Industrial Machinery/Components
- BOLD
- Sector
- BODI Industrials
- BOLD
- Exchange
- BODI Nasdaq
- BOLD Nasdaq
- Market Cap
- BODI 28.3M
- BOLD 30.3M
- IPO Year
- BODI N/A
- BOLD 2024
- Fundamental
- Price
- BODI $4.71
- BOLD $1.49
- Analyst Decision
- BODI Strong Buy
- BOLD Hold
- Analyst Count
- BODI 3
- BOLD 1
- Target Price
- BODI $10.67
- BOLD N/A
- AVG Volume (30 Days)
- BODI 23.1K
- BOLD 57.3K
- Earning Date
- BODI 05-14-2025
- BOLD 05-09-2025
- Dividend Yield
- BODI N/A
- BOLD N/A
- EPS Growth
- BODI N/A
- BOLD N/A
- EPS
- BODI N/A
- BOLD N/A
- Revenue
- BODI $418,796,000.00
- BOLD N/A
- Revenue This Year
- BODI N/A
- BOLD N/A
- Revenue Next Year
- BODI N/A
- BOLD N/A
- P/E Ratio
- BODI N/A
- BOLD N/A
- Revenue Growth
- BODI N/A
- BOLD N/A
- 52 Week Low
- BODI $3.70
- BOLD $1.06
- 52 Week High
- BODI $9.90
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- BODI 47.11
- BOLD N/A
- Support Level
- BODI $3.79
- BOLD N/A
- Resistance Level
- BODI $5.36
- BOLD N/A
- Average True Range (ATR)
- BODI 0.40
- BOLD 0.00
- MACD
- BODI 0.19
- BOLD 0.00
- Stochastic Oscillator
- BODI 57.39
- BOLD 0.00
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.